{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:17:32Z","timestamp":1787498252852,"version":"build-2736575974"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.biomaterials.2022.121783","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T23:29:40Z","timestamp":1662074980000},"page":"121783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Sustained potentiation of bystander killing via PTEN-loss driven macropinocytosis targeted peptide-drug conjugate therapy in metastatic triple-negative breast cancer"],"prefix":"10.1016","volume":"289","author":[{"given":"Young Seok","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha Rin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Jin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Woo","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Gun","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Hye","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8997-448X","authenticated-orcid":false,"given":"Jinu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Kyoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3168-7189","authenticated-orcid":false,"given":"Jeong Uk","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2162-7983","authenticated-orcid":false,"given":"Sang Yoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3863-2236","authenticated-orcid":false,"given":"Youngro","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.biomaterials.2022.121783_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/genes11070719","article-title":"PTEN alterations and their role in cancer management: are we making headway on precision medicine?","volume":"11","author":"Fusco","year":"2020","journal-title":"Genes"},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121783_bib2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.cell.2014.03.027","article-title":"Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function","volume":"157","author":"Papa","year":"2014","journal-title":"Cell"},{"issue":"41","key":"10.1016\/j.biomaterials.2022.121783_bib3","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1038\/onc.2008.241","article-title":"PTEN: a new guardian of the genome","volume":"27","author":"Yin","year":"2008","journal-title":"Oncogene"},{"issue":"19","key":"10.1016\/j.biomaterials.2022.121783_bib4","doi-asserted-by":"crossref","first-page":"32043","DOI":"10.18632\/oncotarget.16761","article-title":"Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.biomaterials.2022.121783_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11091401","article-title":"Prognostic and predictive implications of PTEN in breast cancer: unfulfilled promises but intriguing perspectives","volume":"11","author":"Carbognin","year":"2019","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121783_bib6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ijc.28021","article-title":"Comprehensive analysis of PTEN status in breast carcinomas","volume":"133","author":"Jones","year":"2013","journal-title":"Int. J. Cancer"},{"issue":"7418","key":"10.1016\/j.biomaterials.2022.121783_bib7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Genome Atlas, Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer","year":"2012","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.biomaterials.2022.121783_bib8","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/annonc\/mdz133","article-title":"Targeting the PI3-kinase pathway in triple-negative breast cancer","volume":"30","author":"Pascual","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biomaterials.2022.121783_bib9","article-title":"The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes","volume":"7","author":"Pereira","year":"2016","journal-title":"Nat. Commun."},{"issue":"37","key":"10.1016\/j.biomaterials.2022.121783_bib10","doi-asserted-by":"crossref","first-page":"60712","DOI":"10.18632\/oncotarget.10858","article-title":"Triple negative breast cancer: shedding light onto the role of pi3k\/akt\/mtor pathway","volume":"7","author":"Massihnia","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121783_bib11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000455821","article-title":"Therapeutic advances and new directions for triple-negative breast cancer","volume":"12","author":"Andreopoulou","year":"2017","journal-title":"Breast Care"},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121783_bib12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/1389450114666140106100909","article-title":"Therapeutic targeting of cancers with loss of PTEN function","volume":"15","author":"Dillon","year":"2014","journal-title":"Curr. Drug Targets"},{"issue":"30","key":"10.1016\/j.biomaterials.2022.121783_bib13","doi-asserted-by":"crossref","first-page":"48206","DOI":"10.18632\/oncotarget.10195","article-title":"Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers","volume":"7","author":"Hatem","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.biomaterials.2022.121783_bib14","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(17)30450-3","article-title":"Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"18","author":"Kim","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biomaterials.2022.121783_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.662232","article-title":"AKT inhibitors: new weapons in the fight against breast cancer?","volume":"12","author":"Martorana","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121783_bib16","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13058-020-01354-y","article-title":"Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer","volume":"22","author":"Garrido-Castro","year":"2020","journal-title":"Breast Cancer Res."},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121783_bib17","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ccr.2009.03.020","article-title":"Ligand-independent HER2\/HER3\/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941","volume":"15","author":"Junttila","year":"2009","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.biomaterials.2022.121783_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071538","article-title":"Mechanisms of resistance to PI3K inhibitors in cancer: adaptive responses, drug tolerance and cellular plasticity","volume":"13","author":"Wright","year":"2021","journal-title":"Cancers"},{"issue":"357","key":"10.1016\/j.biomaterials.2022.121783_bib19","doi-asserted-by":"crossref","first-page":"ra121","DOI":"10.1126\/scisignal.aaa1877","article-title":"Systematic identification of signaling pathways with potential to confer anticancer drug resistance","volume":"7","author":"Martz","year":"2014","journal-title":"Sci. Signal."},{"issue":"4","key":"10.1016\/j.biomaterials.2022.121783_bib20","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1158\/2159-8290.CD-18-1175","article-title":"Challenges for the clinical development of PI3K inhibitors: strategies to improve their impact in solid tumors","volume":"9","author":"Hanker","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biomaterials.2022.121783_bib21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41523-020-00197-2","article-title":"Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies","volume":"6","author":"Marra","year":"2020","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121783_bib22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"issue":"11","key":"10.1016\/j.biomaterials.2022.121783_bib23","first-page":"1233","article-title":"Understanding and treating triple-negative breast cancer","volume":"22","author":"Anders","year":"2008","journal-title":"Oncology"},{"issue":"11","key":"10.1016\/j.biomaterials.2022.121783_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113271","article-title":"Breast cancer heterogeneity and response to novel therapeutics","volume":"12","author":"Baliu-Pique","year":"2020","journal-title":"Cancers"},{"issue":"7538","key":"10.1016\/j.biomaterials.2022.121783_bib25","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nature13948","article-title":"Convergent loss of PTEN leads to clinical resistance to a PI(3)Kalpha inhibitor","volume":"518","author":"Juric","year":"2015","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121783_bib26","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/nm.3841","article-title":"Studying clonal dynamics in response to cancer therapy using high-complexity barcoding","volume":"21","author":"Bhang","year":"2015","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121783_bib27","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s13346-018-0551-3","article-title":"Metastatic and triple-negative breast cancer: challenges and treatment options","volume":"8","author":"Al-Mahmood","year":"2018","journal-title":"Drug Deliv Transl Res"},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121783_bib28","doi-asserted-by":"crossref","first-page":"249","DOI":"10.46883\/ONC.2021.3505.0249","article-title":"Novel therapies for metastatic triple-negative breast cancer: spotlight on immunotherapy and antibody-drug conjugates","volume":"35","author":"Nagayama","year":"2021","journal-title":"Oncology"},{"issue":"10","key":"10.1016\/j.biomaterials.2022.121783_bib29","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41568-018-0048-x","article-title":"Nutrient scavenging in cancer","volume":"18","author":"Finicle","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121783_bib30","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.trecan.2019.04.002","article-title":"Macropinocytosis in cancer: a complex signaling network","volume":"5","author":"Zhang","year":"2019","journal-title":"Trends Cancer"},{"issue":"Pt 1","key":"10.1016\/j.biomaterials.2022.121783_bib31","first-page":"1","article-title":"PTEN function: how normal cells control it and tumour cells lose it","volume":"382","author":"Leslie","year":"2004","journal-title":"Biochem. J."},{"key":"10.1016\/j.biomaterials.2022.121783_bib32","article-title":"The dual role of macropinocytosis in cancers: promoting growth and inducing methuosis to participate in anticancer therapies as targets","volume":"10","author":"Song","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biomaterials.2022.121783_bib33","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fendo.2017.00261","article-title":"Macropinocytosis: a metabolic adaptation to nutrient stress in cancer","volume":"8","author":"Recouvreux","year":"2017","journal-title":"Front. Endocrinol."},{"issue":"1765","key":"10.1016\/j.biomaterials.2022.121783_bib34","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2018.0285","article-title":"Metabolic functions of macropinocytosis","volume":"374","author":"Palm","year":"2019","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"issue":"19","key":"10.1016\/j.biomaterials.2022.121783_bib35","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1101\/gad.228122.113","article-title":"Exploiting the bad eating habits of Ras-driven cancers","volume":"27","author":"White","year":"2013","journal-title":"Genes Dev."},{"issue":"14","key":"10.1016\/j.biomaterials.2022.121783_bib36","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1242\/jcs.176149","article-title":"Uses and abuses of macropinocytosis","volume":"129","author":"Bloomfield","year":"2016","journal-title":"J. Cell Sci."},{"issue":"7","key":"10.1016\/j.biomaterials.2022.121783_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201800368","article-title":"Self-triggered apoptosis enzyme prodrug therapy (STAEPT): enhancing targeted therapies via recurrent bystander killing effect by exploiting caspase-cleavable linker","volume":"5","author":"Chung","year":"2018","journal-title":"Adv. Sci."},{"key":"10.1016\/j.biomaterials.2022.121783_bib38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jconrel.2019.01.020","article-title":"The novel strategy for concurrent chemoradiotherapy by conjugating the apoptotic cell-binding moiety to caspase-3 activated doxorubicin prodrug","volume":"296","author":"Cho","year":"2019","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2022.121783_bib39","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.biomaterials.2018.11.001","article-title":"Highly potent monomethyl auristatin E prodrug activated by caspase-3 for the chemoradiotherapy of triple-negative breast cancer","volume":"192","author":"Chung","year":"2019","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121783_bib40","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju403","article-title":"Induced phenotype targeted therapy: radiation-induced apoptosis-targeted chemotherapy","volume":"107","author":"Lee","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.biomaterials.2022.121783_bib41","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jconrel.2022.02.026","article-title":"Albumin metabolism targeted peptide-drug conjugate strategy for targeting pan-KRAS mutant cancer","volume":"344","author":"Cho","year":"2022","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2022.121783_bib42","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jconrel.2022.04.014","article-title":"Caspase-3 mediated switch therapy of self-triggered and long-acting prodrugs for metastatic TNBC","volume":"346","author":"Kim","year":"2022","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2022.121783_bib43","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ctrv.2018.04.010","article-title":"The role of PARP inhibition in triple-negative breast cancer: unraveling the wide spectrum of synthetic lethality","volume":"67","author":"Papadimitriou","year":"2018","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.biomaterials.2022.121783_bib44","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.2147\/CMAR.S215729","article-title":"Beyond the T\/C ratio: old and new anticancer activity scores in vivo","volume":"11","author":"Ubezio","year":"2019","journal-title":"Cancer Manag. Res."},{"issue":"Suppl 4","key":"10.1016\/j.biomaterials.2022.121783_bib45","first-page":"65","article-title":"Growth rate analysis and efficient experimental design for tumor xenograft studies","volume":"13","author":"Hather","year":"2014","journal-title":"Cancer Inf."},{"issue":"4","key":"10.1016\/j.biomaterials.2022.121783_bib46","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.3390\/molecules19044924","article-title":"The synergistic biologic activity of oleanolic and ursolic acids in complex with hydroxypropyl-gamma-cyclodextrin","volume":"19","author":"Soica","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.biomaterials.2022.121783_bib47","article-title":"beta-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121783_bib48","article-title":"Autophagy inhibition contributes to the synergistic interaction between EGCG and doxorubicin to kill the hepatoma Hep3B cells","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121783_bib49","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2022.121783_bib50","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3389\/fonc.2014.00318","article-title":"Connection between tumor suppressor BRCA1 and PTEN in damaged DNA repair","volume":"4","author":"Minami","year":"2014","journal-title":"Front. Oncol."},{"issue":"6\u20137","key":"10.1016\/j.biomaterials.2022.121783_bib51","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/emmm.200900041","article-title":"Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors","volume":"1","author":"Mendes-Pereira","year":"2009","journal-title":"EMBO Mol. Med."},{"issue":"7","key":"10.1016\/j.biomaterials.2022.121783_bib52","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/djy085","article-title":"Biomarkers for homologous recombination deficiency in cancer","volume":"110","author":"Hoppe","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121783_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11050732","article-title":"Targeting cancer stem cells: a strategy for effective eradication of cancer","volume":"11","author":"Shibata","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121783_bib54","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41392-020-00430-1","article-title":"Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents","volume":"6","author":"Zhou","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.biomaterials.2022.121783_bib55","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3389\/fonc.2020.00570","article-title":"Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors","volume":"10","author":"Vikas","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121783_bib56","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","article-title":"Combination strategies to maximize the benefits of cancer immunotherapy","volume":"14","author":"Zhu","year":"2021","journal-title":"J. Hematol. Oncol."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961222004239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961222004239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T17:13:37Z","timestamp":1758906817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961222004239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":56,"alternative-id":["S0142961222004239"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121783","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sustained potentiation of bystander killing via PTEN-loss driven macropinocytosis targeted peptide-drug conjugate therapy in metastatic triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121783","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"121783"}}